Sorafenib Tosylate (cas 475207-59-1)
Compound Information: Sorafenib Tosylate
| Category | Details |
|---|---|
| Name | Sorafenib Tosylate |
| CAS Number | 475207-59-1 |
| Synonyms | BAY 43-9006 Tosylate; Nexavar; Sorafenib Methanesulfonate |
| EINECS Number | 641-758-8 |
| Molecular Formula | C₂₁H₁₆ClF₃N₄O₃·C₇H₈O₃S |
| Molecular Weight | 637.03 g/mol |
| Chemical Properties | |
| – Melting Point | 229–232°C |
| – Storage Temp. | Keep in dark, sealed, dry at 2–8°C |
| – Solubility | Soluble in DMSO (up to 200 mg/mL), slightly soluble in ethanol (3 mg/mL) |
| – Form | Solid |
| – Color | Off-white |
| – Stability | Stable for 2 years as supplied; solutions in DMSO/ethanol stored at -20°C for ≤1 month |
| InChIKey | IVDHYUQIDRJSTI-UHFFFAOYSA-N |
Key Notes:
- Chemical Structure:
- A methanesulfonate salt of sorafenib, a multi-kinase inhibitor targeting VEGFR, PDGFR, Raf, and KIT.
- Contains a chloro-substituted aromatic core with a urea linker for enhanced target binding.
- Pharmacological Role:
- Oral administration for advanced cancers (e.g., renal cell carcinoma, hepatocellular carcinoma).
- Inhibits angiogenesis and tumor proliferation via VEGFR2/3 and Raf/MEK/ERK pathway blockade.
- Clinical Use:
- Approved indications:
- Advanced renal cell carcinoma (RCC).
- Unresectable hepatocellular carcinoma (HCC).
- Differentiated thyroid cancer (DTC) resistant to radioactive iodine.
- Dosage: 400 mg (2×200 mg tablets) twice daily, adjusted for toxicity.
- Approved indications:
- Safety & Toxicity:
- Common side effects: Rash, diarrhea, hypertension, fatigue, hand-foot skin reactions.
- Severe risks: Liver toxicity, gastrointestinal bleeding, severe skin reactions.
- Supplier Information:
- Pricing: ~$0.3–5/mg (varies by purity and order volume).
Analytical & Handling Guidelines:
- Detection: HPLC-MS for purity and metabolite analysis.
- Stability: Store under inert atmosphere; avoid light and humidity.
sale@pharma-peptides.com
请到「后台-用户-个人资料」中填写个人说明。